Introduction
The standard of care for muscle invasive or bacillus Calmette-Guérin high-grade, refractory bladder cancer is open radical cystectomy (ORC) with pelvic lymph node (LN) dissection and urinary reconstruction. ORC is associated with considerable rates of perioperative morbidity and mortality. During the past several years, the benefits of robotic assistance during minimally invasive surgery have been demonstrated for a variety of surgical techniques in urology. 1 Given the morbidity of ORC, the natural evolution of surgical practice was to attempt to incorporate robotic assistance. Robotic-assisted radical cystectomy (RARC) was first described by Menon et al 2 and has since been reported in multiple academic and large-volume centers. 3 The values of decreased surgical blood loss, lower incidence of ileus, quicker return to activities of daily living, and the decreased use of narcotics for pain management following surgery have fueled the arguments in favor of RARC. 4 Appropriate patient selection and understanding the learning curve, costs, and perioperative and oncological outcomes are all debated topics, and such concerns have mainly been addressed by utilizing retrospective experience, thus limiting high-quality evidence.
Methods
We performed a systematic search of the medical literature using the keywords "cystectomy," "robotics," "robotic cystectomy," and "lymph node dissection." We found that a single randomized controlled trial (RCT) had been published comparing ORC and RARC. 5 However, a thorough assessment of the details of that study is limited by lack of available published data. Aside from that study, level 1/2 evidence is lacking to evaluate the efficacy and utility of RARC. Hence, most of the studies selected were contemporary retrospective reviews.
Emphasis was placed on studies published with-steep Trendelenburg position or prolonged pneumoperitoneum.
Perioperative Considerations
Bowel preparation similar to what is employed for ORC can be performed for RARC and is typically based on surgeon preference. Mechanical bowel preparation is usually omitted for patients undergoing an ileal conduit but can be given (eg, 1-2 bottles of magnesium citrate) prior to undergoing a continent diversion. A fleet enema should be administered for all patients regardless of urinary diversion performed should rectal injury occur. 16, 17 With the exception of urinary reconstruction, in the previous 5 years. Reports were reviewed and selected based on their scientific merit. Upon review of the initially selected manuscripts, frequently cited studies were also included.
Patient Selection
The studies that directly compare ORC with RARC are listed in Table 1 . 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Traditionally, RARC is reserved for healthy patients with minimal prior pelvic or abdominal surgeries who can tolerate pneumoperitoneum; for experienced surgeons, RARC can be performed in more complex cases. Comparative studies have demonstrated that RARC can be offered to patients presenting with locally advanced disease, a higher body mass index (BMI), or an increased American Society of Anesthesiologists (ASA) score. Among those studies that incorporated RARC, the median age of participants was between 65.5 and 70 years of age, median BMI was between 26.5 and 27.6 kg/m 2 , and 14% to 78% of patients had ASA scores of 3 or higher. 6, 7 Butt et al 8 examined the effect of obesity on perioperative outcomes for robotic cystectomy. In their cohort, 71% of patients were either overweight or obese; their mean BMI was 28.0 kg/m 2 . No differences were seen in the rate of estimated blood loss (EBL), complications, or operative time between those with a normal BMI and those who were overweight or obese. However, those who were obese and had pT3 to pT4 disease had an increased rate of positive margins. 8 Even though the largest cohort consisted of 227 patients, an equal distribution of patients with locally advanced bladder cancer and multiple comorbidities was represented. 8 The preoperative routine for patients undergoing RARC should be similar to ORC. Standard contraindications apply to all patients, including uncorrected coagulopathy, severe ascites, or advanced disease. Careful consideration should be given to those patients with significant pulmonary disease, which may preclude them from tolerating a All studies included in this review found a statistically significant benefit of decreased operative blood loss in favor of RARC. This is due to several reasons: (1) the increased/magnified, 3-dimensional visualization that the robot provides in identifying anatomical landmarks, structures, and vessels (including ligation of the dorsal venous complex), and (2) the ability to operate while under pneumoperitoneum. The rate of EBL ranged (median or mean) from 475 to 1351 cc for ORC and 200 to 423 cc for RARC. 7, [9] [10] [11] 19 Although the rate of EBL is subject to reporter variability and a learning curve is associated with RARC, improvements seen with decreased rates of EBL were substantial.
Nix et al 9 demonstrated an improvement in the required use of narcotics during patients' hospital stay to manage pain among those undergoing RARC compared with ORC. The in-hospital pain regimen, which was measured by morphine sulfate equivalents, decreased from 151.6 mg (mean) to 93.6 mg for those undergoing RARC. 9 This finding was further substantiated by Guru et al. 20 Although their cohort was small (N = 33; n = 17 ORC, n = 16 RARC), Guru et al 20 saw a decrease in morphine sulfate equivalents for each postoperative day in favor of RARC; however, the average daily pain scores reported by the patients were similar for both approaches.
Similarities and differences with regard to length of hospital stay, complications, and pathological outcomes are highlighted in Table 2 . 4, [6] [7] [8] [9] [10] [11] [13] [14] [15] 21 The results from 1 RCT demonstrated no differences in hospital stays or 90-day complication rates between the 2 surgical modalities. 18 The mean hospital stay for ORC and RARC was 8 days.
18 However, the study had limitations. It consisted of a single center experience (Memorial Sloan Kettering Cancer Center, New York), open urinary reconstructions, no surgeon crossover, and patients undergoing robotic-assisted LN dissections to the aortic bifurcation and inferior mesentery artery more frequently than open surgery.
18 By contrast, 25 In a noninferior RCT comparing PLND between RARC and ORC in 41 study participants, RARC was found to be noninferior to ORC. 9 The average LNs removed were 19 for RARC and 18 for ORC. 9 
Quality of Life
Using the Convalescence and Recovery Evaluation (CARE) to assess the quality of life after RARC, Stegemann et al 12 sought to compare patient outcomes at 90 days compared with baseline (before surgery). CARE is a questionnaire that evaluates patient postoperative recovery in the areas of gastrointestinal, activity, pain, and cognitive-related symptoms following abdominal procedures. 26 The 91 study participants preoperatively and postoperatively evaluated came close to reaching their presurgical baseline levels at 90 days, except for areas related to the gastrointestinal system. 12 The average time it took for patients to reach 90% in the overall CARE difference index (ie, the time it took for patients to return to 90% of their baseline) was 63 days.
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Intracorporeal Diversion
One of the more controversial debates in RARC cohorts is urinary reconstruction. Intracorporeal urinary reconstruction can be the most technically challenging portion of the operation and can represent a barrier to adoption of the surgical technique. 27 Jonsson et al 28 reported on perioperative outcomes in a nonrandomized trial of 45 study participants (36 receiving an intracorporeal neobladder and 9 receiving an intracorporeal ileal conduit). Median operative times were 480 minutes for the neobladder (range, 330-760 minutes) and 460 minutes for an ileal conduit (range, 325-561 minutes). 28 The rates of EBL were 625 and 350 cc for those undergoing a neobladder and ileal conduit, respectively.
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A total of 40% of patients had early complications (≤ 30 days) and 33% presented with late complications (> 30 days). 28 When comparing the first 18 neobladders to the second 18 neobladders, the median operative time decreased from 517 to 417 minutes. 28 The same decline was seen with early and late complications (50% to 28% and 50% to 17%, respectively).
In a similar fashion, Canda et al 29 showed the feasibility of performing an intracorporeal neobladder and an ileal conduit in their first 27 cases. They data from the US Nationwide Inpatient Sample demonstrated a cumulative decrease in overall complications (49.1% for RARC and 63.8% for ORC; P = .035); however, differences in a particular type of complication could not be distinguished. 3 This study did cite several limitations, including the unavailability of certain patient characteristics (eg, BMI) and the inability to identify which patients received prior radiation, to distinguish readmissions, late complications, and to identify the different degree and severity of complications. 3 In an evaluation of elderly persons 75 years of age and older, Richards et al 22 retrospectively examined the data of 40 patients (20 ORC and 20 RARC) to determine perioperative outcomes. No differences were seen in patient BMI, ASA score, or number of prior abdominal surgeries between ORC and RARC. 22 Significant differences were seen in length of hospital stay (7 for RARC and 14.5 days for ORC) and Clavien-Dindo complications of grade 3 or higher (10% for RARC and 35% for ORC).
22
Oncological Outcomes
As seen in Table 2 , positive margin rates ranged from 0% to 12% and were not significantly different. 4, [6] [7] [8] [9] [10] [11] [13] [14] [15] 21 One can reasonably suspect that selection bias played a role in the margin status. It is possible that patients who received prior pelvic radiation (for prostate or bladder cancer) or those with locally advanced bladder cancer were ineligible to undergo robotic-assisted cystectomy (by surgeon preference) and, hence, may have falsely lowered the positive margin rates. Nonetheless, if key principles of the operation are followed, with meticulous dissection, positive margin rates will be optimized regardless of surgical approach.
To evaluate long-term survival rates in patients undergoing RARC, Khan et al 6 evaluated 14 patients with follow-up times of 5 years or more. Overall survival, disease-specific, and disease-free survival rates were reported to be 64%, 75%, and 50%, respectively. 6 Three of the patients died after developing distant metastasis and another 3 had disease recurrence in 44 to 77 months. 6 However, large, long-term, well-controlled studies are needed to prove that RARC has the oncological equivalency of ORC. 23 LN dissection measured by LN yield is often considered to be a criterion for the adequacy of a surgical technique. Previous studies have demonstrated that an LN dissection has staging and therapeutic benefit. Davis et al 24 performed open pelvic LN dissection (PLND) after robotically dissecting the pelvic LNs in 11 patients. The dissection consisted of the bilateral obturator, external, and common iliac artery regions without or in combination with the presacral and para-aortic/paracaval zones. The median LN count was 43 for robotic-assisted PLNDs, with an additional reported an average operative time of 9.9 hours (range, 7.1-12.4 hours). Of the 27 study patients, 4 experienced early (≤ 30 days) major (Clavien-Dindo grade ≥ 3) complications and 3 experienced late (> 30 days) major complications. 29 However, it is difficult to make any conclusions about long-term functional outcomes when the longest follow-up was only 12 months.
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Cost Analysis
Although challenging, the extrapolation of costs for adopting RARC is an important point to consider. One report concluded that the application of the robot increased direct costs for radical cystectomy by $1,600. 
Learning Curve
Determining the number of cases needed to become proficient with robotic-assisted cystectomy is difficult. Knowledge of pelvic anatomy and the principles of ORC are mandatory prerequisites. However, when the rate of EBL, the positive margin rate, and the number of LNs removed are used as variables to define the quality of RARC, the International Robotic Cystectomy Consortium deemed 30 cases to be the "acceptable level of proficiency" in performing RARC. 21 Richards et al 31 evaluated the learning curve for RARC by using patient outcomes. The first 60 cases by junior faculty, under mentorship from an experienced surgeon, were retrospectively reviewed and subdivided by tertiles. Between tertiles, no statistical difference was seen with regard to total operating room time, rate of EBL, hospital stay, or soft-tissue positive margins (5%-20%). 31 However, the amount of total complications was increased (early [< 90 days] and late [> 90 days]) in the first 20 cases (70%) compared with the last 20 cases (30%). 31 In a similar study with a single surgeon, Hayn et al 32 examined the outcomes of 164 consecutive study patients undergoing RARC. The decision to incorporate this new technique came after completing 100 prior robotic-assisted retropubic prostatectomies. To evaluate rates of improvement, cases were classified as 50 or less, 51 to 100, or more than 100. 32 No statistical differences were noted between incidence of complications, rate of positive surgical margins, The study researchers will examine cancer outcomes (2-year, progression-free survival rates), surgical complications, and quality-of-life issues between ORC and RARC. Accrual has been completed and the study results are expected in 2017. 33 
